177lu-dota-eb-tate
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2017 (NCT03308682)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06991738 | Phase 1/Phase 2 (Phase 2) | Dec 2, 2025 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT05475210 | Phase 1 | Jun 18, 2022 | ClinSmart, Memorial Sloan-Kettering Cancer Center, Molecular Targeting Technologies, Inc. |
| NCT03308682 | Phase 1 | Apr 30, 2017 | Chinese Academy of Medical Sciences, National Institutes of Health (NIH), Tsinghua University |
| NCT03478358 | Phase 1 | Apr 30, 2017 | Chinese Academy of Medical Sciences, National Institutes of Health (NIH), Tsinghua University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 1 | 2017 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2017 |
| Tsinghua University | Academic/Hospital | 2 | 0 | 1 | 2017 |
| ClinSmart | For profit | 1 | 0 | 1 | 2022 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Molecular Targeting Technologies, Inc. | For profit | 1 | 1 | 1 | 2022 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2025 |
7 organizations
Page 1 / 1